Coverage
-
June 02, 2026
A Spectrum Pharmaceuticals Inc. investor has asked a New York federal court to approve a $7 million deal resolving class action claims alleging the drugmaker overstated its regulatory prospects for winning approval for a cancer treatment.
3 other articles on this case.
View all »